<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230717058818N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-21</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of Entonex gas with Bl32 and sp6 pressure points on labor pain, labor stages and labor outcomes</public_title>
      <acronym>IEPS</acronym>
      <scientific_title>Comparison of the effect of Entonex gas with Bl32 and sp6 pressure points on labor pain, labor stages and labor outcomes in primiparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71445</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: After receiving written consent, 90 patients will be randomly divided into three groups: Entonex, acupressure, and control, so that there will be 30 people in each group. Balance block randomization method will be used for random and the stata software allocation of people and the ralloc package will be used to create a random sequence. .In this way, 6 blocks with 1 permutation will be created in the following order:
1=ABC
2=ACB
3=CAB
4=CBA
5=BCA
6=BAC
Where A represents the Entonex group, B represents the acupressure group and C represents the control group. Then, based on the numbers in the random table, a number will be chosen randomly, and based on the last digit on the right, one of the groups will be used to determine the sequence of randomization. It should be noted that if the number on the right is zero or 7 to 9 when choosing a random number, that number will not be considered and a random number will be selected again. This will continue until all 90 people are assigned to three groups. It should be noted that this method will prevent two groups from being unbalanced, as well as identifying the randomization sequence.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Labor duration, labor pain and maternal and fetal complications after delivery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: entonex.Until the client learns how to use the Entonx mask and capsule and identify uterine contractions, the training will continue, and Entonx gas with a mask will be used as self-prescription from the beginning to the end of each uterine contraction. Intervention 2: Intervention group: point pressures.Acupressure will be performed at BL32 and SP6 points, and pressure will be applied during uterine contractions by two hands of the researcher on both sides. After 30 seconds of pressure, a 30-second rest will be given. In this way, it will continue for 20 minutes, and each time One of these two points is pressed bilaterally, and the instructor will stay with the researcher until the complete training on how to perform acupressure. Intervention 3: Control group: control.The control group received only routine measures.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Clinical study report, results are shared

When:
Access starts one year after the results are published

To whom:
Researchers working in academic institutions

Conditions:
Analytical studies

Where to obtain:
gheitasi-s@medilam.ac.ir
Shaghayegh Gheitasiilami

How to obtain:
Information will be sent after the request is reviewed and if the ethical points of the research and the consent of the participants are met.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shaghayegh Gheitasiilami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.5,Resalat Ave,Rasalat Street,Ilam Town</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6831956599</zip>
        <telephone>+98 84 3333 3333</telephone>
        <email>gheitasi-s@medilam.ac.ir</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shaghayegh Gheitasiilami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.5,Resalat Ave,Resalat Street,Ilam Town</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931956599</zip>
        <telephone>+98 84 3333 3333</telephone>
        <email>gheitasi-s@medilam.ac.ir</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Consent to participate in the study
Having literacy
Singleton pregnancy
Gestational age 37 to 41 weeks
Fetal cephalic status
Women being in the active phase
Not suffering from mental disorders
No Anatomical disorders
Not using other methods of anesthesia
Not using oxytocin to induce and strengthen labor</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Multiple pregnancy
Mother's chronic illness
Skin diseases such as eczema
high risk pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: entonex.Until the client learns how to use the Entonx mask and capsule and identify uterine contractions, the training will continue, and Entonx gas with a mask will be used as self-prescription from the beginning to the end of each uterine contraction.</i_keyword>
      <i_keyword>Intervention group: point pressures.Acupressure will be performed at BL32 and SP6 points, and pressure will be applied during uterine contractions by two hands of the researcher on both sides. After 30 seconds of pressure, a 30-second rest will be given. In this way, it will continue for 20 minutes, and each time One of these two points is pressed bilaterally, and the instructor will stay with the researcher until the complete training on how to perform acupressure.</i_keyword>
      <i_keyword>Control group: control.The control group received only routine measures.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Labor progress. Timepoint: 4 cm dilatation, every one hour during intervention and after delivery. Method of measurement: Checklist of Duration of Labor Stages.</prim_outcome>
      <prim_outcome>Labor pain. Timepoint: one hour during labor. Method of measurement: Ten Degree Visual Analogue scale.</prim_outcome>
      <prim_outcome>Maternal and Neonatal Outcomes. Timepoint: After giving birth and the day after giving birth. Method of measurement: Checklist of Maternal and Neonatal Outcomes.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Maternal and neonatal complications after delivery. Timepoint: Before birth and one day after delivery. Method of measurement: Checklist of maternal and newborn outcomes designed by the researcher.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-14</approval_date>
        <contact_name>Ethics committee of Ilam University of Medical Sciences</contact_name>
        <contact_address>No.5.Resalat Ave,resalat street,Ilam Town Ilam Ilam Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
